Please login to the form below
ozanimod
This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis
Bristol Myers Squibb (BMS) has shared new long-term data from a study evaluating Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (RMS).
Latest news
-
BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients
Bristol Myers Squibb (BMS) has announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia (ozanimod) from the ongoing phase 3 DAYBREAK
-
Bristol Myers Squibb’s active ulcerative colitis treatment bags NICE recommendation
Bristol Myers Squibb's (BMS) Zeposia (ozanimod) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with moderate-to-severe active ulcerative
-
Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
The collaboration adds to BMS’ IBD portfolio, which currently includes Zeposia (ozanimod), approved for ulcerative colitis and multiple sclerosis, as well as deucravacitinib for the treatment of patients with severe ulcerative
-
Bristol Myers Squibb announces positive trial results for treatment of MS
Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis
-
Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. ... Bristol Myers Squibb has announced interim results from the phase 3 extension trial DAYBREAK,
More from news
Approximately 5 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the
-
20 for 2020 – Five pharma companies to watch
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
-
Pharma deals in July 2015
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Redbow Consulting Group
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
